COMPASSIONATE ALLOWANCE INFORMATION
Mature Ectomesenchymoma; Gangliorhabdomyosarcoma; Rhabdomyosarcoma with Ganglionic Differentiation
Malignant Ectomesenchymoma is a rare, potentially aggressive tumor (a type of primitive neuroectodermal tumor or PNET). It may originate in the central nervous system or soft tissue of the head and neck, abdomen, perineum, scrotum or limbs. It occurs mostly in children.
DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND ICD-9-CM CODING
Diagnostic testing: Testing for malignant ectomesenchymoma tumors includes imaging studies (CT, MRI, or nucleide scans such as liver-spleen scans); spinal tap for cerebrospinal fluid cytology; urinary catecholamines; and bone marrow biopsy.
Physical findings: Depends on the location of the tumor.
ICD-9: 191.X and other codes, depending upon site
ONSET AND PROGRESSION
These tumors largely affect children under 15 years of age and about 20% are found in adults. Increasing experience with the treatment of malignant ectomesenchymoma via appropriate surgical approaches, and combination chemotherapy and radiotherapy, may offer a better prognosis for children presenting with this rare and complex tumor.
The treatment of this type of tumor depends on the stage of the cancer at the time of diagnosis, the amount of tumor remaining after surgery to remove it or whether the tumor has spread to other places in the body (metastases), age of the individual at the time of diagnosis, recurrence, and response to chemotherapy and/or radiation therapy.
SUGGESTED PROGRAMMATIC ASSESSMENT*
Suggested MER for evaluation:
Suggested Listings for Evaluation:
Meets 13.13A3/113.13C in adults and children if originating in the brain and has documented metastases; also meets 13.13A3/113.13C in adults/children if it is recurrent cancer. Meets 113.03 in children when originating outside of the brain. Meets 13.04 in adults if originating outside of the brain and has metastases or is recurrent.
| || |
* Adjudicators may, at their discretion, use the Medical Evidence of Record or Listings suggested to evaluate the claim. However, the decision to allow or deny the claim rests with the adjudicator.